Mater Group

Experts Share Insights on Evolving Global Vaccine Landscape Including mRNA Trends

Retrieved on: 
금요일, 3월 3, 2023
Research, European, Mater Group, NEXT Woman of the Year awards, Royal college, Australasian, University of the Philippines Manila, Consultant, Senior, Editor-in-chief, Toxicology, IND, Protein, University, Royal Australasian College, Infection, COVID-19, ChromeOS, Marie Cassidy, Associate, Acquisition, Tropical medicine, Principal, Vaccine, Clinical trial, IVI, Drug development, Pharmacist, International Vaccine Institute, Licensure, SOP, Drug Development and Industrial Pharmacy, Medical microbiology, SK, Babaji, Pharmaceutical industry, Fine chemical, Pharmacology, Physician, Medicine

Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.

Key Points: 
  • Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
  • Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
  • Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • The acquisition is part of Novotech’s global expansion program in Europe and the US.

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
수요일, 2월 15, 2023
University of the Philippines Manila, Toxicology, International Vaccine Institute, Royal college, Marie Cassidy, Acquisition, Clinical trial, Editor-in-chief, Vaccine, Infection, SOP, Protein, SK, University, Drug Development and Industrial Pharmacy, European, NEXT Woman of the Year awards, Royal Australasian College, IVI, Babaji, Pharmacist, Licensure, Research, Mater Group, Medical microbiology, Associate, COVID-19, Principal, ChromeOS, Drug development, Tropical medicine, Senior, Australasian, Consultant, IND, Pharmaceutical industry, Fine chemical, Physician, Medicine, Pharmacology

Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.

Key Points: 
  • Babaji has a strong background in pharmaceutical sciences with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New Zealand.
  • Babaji has experience in small molecules, combination products, and biologicals including vaccines, proteins, monoclonal antibodies, and advanced cell and gene therapies.
  • Novotech has recently acquired EastHORN a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.
  • The acquisition is part of Novotech’s global expansion program in Europe and the US.

The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar

Retrieved on: 
수요일, 2월 15, 2023
University of the Philippines Manila, Toxicology, International Vaccine Institute, Royal college, Marie Cassidy, Acquisition, Clinical trial, Editor-in-chief, Bharat Biotech, Vaccine, Infection, SOP, Protein, SK, University, Drug Development and Industrial Pharmacy, European, Global Jurist of the Year Award, Royal Australasian College, IVI, Babaji, Pharmacist, Licensure, Research, Mater Group, Medical microbiology, Associate, COVID-19, Principal, ChromeOS, AU, Drug development, Tropical medicine, Senior, Australasian, Consultant, IND, Pharmaceutical industry, Fine chemical, Physician, Medicine, Pharmacology

SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.

Key Points: 
  • SYDNEY, AU, Feb 15, 2023 - (ACN Newswire) - Novotech, the leading Asia Pacific centred biotech CRO with extensive experience in vaccine trials, is convening an expert panel webinar covering the evolving landscape in vaccine development.
  • https://novotech-cro.com/whitepapers/vaccines-asia-pacific-clinical-tria...
    The webinar, Keeping pace with the evolving global landscape in vaccine development, will hear from a panel of life science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space including:
    - The COVID-19 impact on drug development and the regulatory landscape.
  • - Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage.
  • - Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.

Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022

Retrieved on: 
월요일, 10월 24, 2022
SAN, Royal Adelaide Hospital, Colon, Disease, Therapy, SEC, Self-microemulsifying drug delivery system, American College of Gastroenterology, Annual report, Patient, Result, Research, Tissue, Financial condition report, GI, Nasdaq, Precision medicine, Private Securities Litigation Reform Act, Goal, Trial of the century, Analysis, ACG, DDS, Mater Group, Pharmacokinetics, Fasting, UC, IBD, Safety, Adalimumab, GLOBE, Ulcerative colitis, Â, Serri, Sardinia, Inflammatory bowel disease, Enema, American College, COVID-19, Medical device, Pharmaceutical industry, Dietary supplement

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the five posters presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which is being held in Charlotte, NC and virtually from October 2126, 2022.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the five posters presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which is being held in Charlotte, NC and virtually from October 2126, 2022.
  • Biora Therapeutics targeted therapeutics platform utilizes a novel approach that could improve IBD patient outcomes by enabling delivery of therapeutics directly to the site of disease.
  • Bioras Drug Delivery System (DDS) is an ingestible capsule designed for targeted delivery of therapeutics to improve treatment of IBD.
  • Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.